In a report released today, Eliana Merle from Cantor Fitzgerald maintained a Hold rating on Ionis Pharmaceuticals Inc (IONS – Research Report), with a price target of $68. The company’s shares closed on Friday at $69.28.
“We think Ionis’ platform has significant potential long term, but in the near term we are cautious around competitive threats. Valuation Summary We use a probability adjusted DCF to value Ionis. We use a probability adjusted DCF to value Ionis.”
According to TipRanks.com, Merle is ranked 0 out of 5 stars with an average return of -10.0% and a 36.4% success rate. Merle covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Aerpio Pharmaceuticals Inc, and CymaBay Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ionis Pharmaceuticals Inc with a $78.50 average price target, representing a 13.3% upside. In a report issued on May 7, Cowen & Co. also maintained a Hold rating on the stock.
Ionis Pharmaceuticals Inc’s market cap is currently $9.56B and has a P/E ratio of 37.48. The company has a Price to Book ratio of 9.12.
Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs.